Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Disorders of Leukocytes01:27

Disorders of Leukocytes

1.3K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.3K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.6K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.6K
Lineage Commitment01:21

Lineage Commitment

3.6K
Commitment is the  process whereby stem cells:
3.6K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Identification of Predictive Biomarkers Based on Cytokine Profiles for Molecular Relapse After Treatment-Free Remission in Chronic Myeloid Leukemia Patients.

Cells·2026
Same author

ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.

Leukemia·2026
Same author

The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Leukemia·2026
Same author

The Influence of the COVID-19 Pandemic in NK Cell Subpopulations from CML Patients Enrolled in the Argentina Stop Trial.

Cells·2025
Same author

Evaluation of leukemic stem cell (CD26 +) in chronic myeloid leukemia patients with different molecular responses and in treatment-free remission.

Clinical and experimental medicine·2025
Same author

Bringing global hematology research to the forefront.

Blood advances·2024
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Oct 23, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.2K

慢性骨髄性白血病

Jorge Cortes1, Carolina Pavlovsky2, Susanne Saußele3

  • 1Georgia Cancer Center, Augusta University, Augusta, GA, USA.

Lancet (London, England)
|August 23, 2021
PubMed
まとめ
この要約は機械生成です。

ティロシンキナーゼ阻害剤は慢性骨髄性白血病患者のほぼ正常な寿命を提供します. 新しい薬剤や治療法に関する研究が進められれば より多くの患者を治すことができるでしょう

さらに関連する動画

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.7K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.8K

関連する実験動画

Last Updated: Oct 23, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.2K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.7K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.8K

科学分野:

  • 血液学
  • 腫瘍学
  • 薬理学について

背景:

  • 慢性骨髄性白血病 (CML) の治療は,チロシンキナーゼ阻害剤 (TKI) によって革新されました.
  • TKIは患者の健康状態を大幅に改善し,多くの患者さんの平均寿命が ほぼ正常になりました.
  • 効果的なCMLの治療には 薬の治療だけでなく 総合的なアプローチが必要です

研究 の 目的:

  • TKIがCMLの自然史に与える影響を検討する.
  • CMLにおける最適な治療反応と長期的な生存を達成するための重要な要素を概説する.
  • 治療中止と新薬を含む,現在と新興のCMLの治療戦略について議論する.

主な方法:

  • 慢性骨髄性白血病のチロシンキナーゼ阻害剤療法に関する現在の文献のレビュー
  • 患者のモニタリング,有害事象の管理,併発症を含む治療の成功に影響を与える要因の分析.
  • 治療停止や新薬の開発など,治療のパラダイムの進化について議論する.

主要な成果:

  • 慢性骨髄性白血病の患者は,適切な治療によって,ほぼ正常な寿命を達成することができます.
  • 最適な反応の特徴,有害事象の管理,併発症の認識は,TKI治療の成功に不可欠です.
  • 治療なしでの寛解は一部のCML患者にとって可能になりつつあり,新薬が耐性症例に開発されています.

結論:

  • ティロシンキナーゼ阻害剤は慢性骨髄性白血病を 高い生存率で管理可能な状態に変えました
  • 副作用や併発症の注意深いモニタリングと管理を含む個別化された治療戦略は不可欠です.
  • CMLの治療における進歩は,治療の中止の可能性と新しい治療法を含めて,ほとんどの患者で最終的な治癒への希望を提供します.